Novo Nordisk A/s

Osteologix A/s

Universitéde Liége

Other

Novo Nordisk Biotech, Inc.

Osteometer Biotech A/s

Nordic Bioscience Diagnostics A/s

Nordic Bioscience Dagnostics A/s

Stephan Christgau

Lene Nonboe Andersen

Markus Sakari Kauppinen

Lene Venke Kofod

Henrik Dalbo Slashedge

Hans Peter Heldt-Hansen

Torben Halkier

Joan Qi Si

Yves Henrotin

Niels Munk

Michelle Deberg

Henrik Dalboege

Jean-Yves Reginster

Hans Sejr Olsen

Christian Hansen

Henrik Nilsson

Claus Dambmann

Per Munk Nielsen

Jack Bech Nielsen

Anette Mullertz

Hendrik Arie Schols

Henrik Dalb&oslash;ge

Claus Christophersen

Jens E T Andersen

Tina Sejersgangrd Jacobsen

Randy M Berka

Claus Crone Fuglsang

Jens Breinholt

Sakari Kauppinen

Dennis Bang Henriksen

Anette M&uuml;llertz

Lene Venke Kofoed

Paul A C Cloos

Alphons Gerard Voragen

Jeff Shuster

Gitte Budolfsen

Per Qvist

Thomas Sandal

Christian Rosenquist

Tina Sejersg&aring;ard Jacobsen

Henry G Bone, Iii

Tina Sejersg&aring;rd Jacobsen

Henrlk Dalbo Slashedge

Jens Et Andersen

Alphons Gerar Voragen

Jens Andersen

Henry G Iii Bone

Paul Andreas Compare Cloos

A combination treatment, wherein a strontium-containing compound together with one or more active substances capable of reducing the incidence of bone fracture and/or increasing bone density and/or improving healing of fractured bone and/or improving bone quality are administered for use in the treatment and/or prophylaxis of cartilage and/or bone conditions.

Combination treatment with strontium for the prophylaxis and/or treatment of cartilage and/or bone conditions

A method for the treatment and/or prophylaxis of an osteonecrotic bone disease in a mammal in need thereof, such as, e.g., idiopathic or secondary osteonecrosis, avascular bone necrosis, glucocorticoid induced bone ischemia/osteonecrosis, Legg-Calve-Perthes disease and femoral head necrosis, the method comprising administering an effective dose of a strontium-containing compound (a) to the mammal. A method for the treatment and/or prophylaxis of an osteonecrotic bone disease, such as, e.g., idiopathic or secondary osteonecrosis, avascular bone necrosis, glucocorticoid induced bone ischemia/osteonecrosis and femoral head necrosis, in a mammal who is to be or is treated with a therapeutic agent (b) known to or suspected of inducing apoptosis and/or necrosis of bone cells, the method comprising administering a strontium-containing compound (a) in combination with (b).

Strontium-containing compounds for use in the prevention or treatment of necrotic bone conditions

Compounds and pharmaceutical compositions for use in the treatment and/or prophylaxis of cartilage and/or bone conditions and for methods of treating such condition. The compounds are salts of strontium that have a water-solubility of from about 1 g/l to about 100 g/l at room temperature, especially amino acid salts of strontium or dicarboxylic acid salts of strontium. Examples of novel water-soluble strontium salts are e.g. strontium glutamate and strontium alpha-ketoglutarate. The present invention also relates to an improved method for preparing the strontium salt of glutamic acid.

Water-soluble strontium salts for use in treatment of cartilage and/or bone conditions

Methods are described for improving the diagnostic possibilities of diseases where oxidative NO-modifications occur, for example inflammatory conditions, cancer, Parkinson's or Alzheimer's disease, and to provide means of monitoring the effects of therapeutical measures taken towards such diseases. The invention enables the detection of disease specific catabolic markers related to oxidative NO-modifications, utilizing an immunoassay comprising antibodies directed against nitrated and non-nitrated epitopes characteristic of a specific protein.

Detection of specific nitrated markers

A new method for preparing salts of metal cations and organic acids, especially divalent salts of alkaline earth metal ions from group II of the periodic system and carboxylic acids. The method comprising the use of a high temperature (about 90&#xb0; or more) and, optionally. high pressure, in order to obtain a higher yield, purity and faster reaction speed than obtained with known synthesis methods. In particular, the present invention relates to the production of strontium salts of carboxylic acids. Novel strontium salts are also provided by the present method.

High yield and rapid synthesis methods for producing metallo-organic salts

A method for improving the diagnostic assessment of cartilage degenerative processes, and to provide means of monitoring the effects of therapeutical measures taken towards arthritic diseases in most mammals utilizes an immunoassay to detect fragments of collagen type II resulting from collagenase activity comprising an antibody directed against an epitope comprised in the amino acid sequence HRGYPGLDG (SEQ ID NO:1), located in the helical region of collagen type II.

Method for monitoring collagen type II degradation in cartilage

In an in vitro diagnostic test for osteoarthritis or rheumatoid arthritis, the amount or presence in a sample of anisomerised or optically inverted protein fragment is measured which derives from perlecan, bigylcan, decorin, fibrillin-1 or protocadherin or which is a specific sequence from aggrecan, type II collagen, COMP or CILP.

Assay of isomerised and/or optically inverted proteins and protein fragments

A method for improving the diagnostic assessment of cartilage degenerative processes, and to provide means of monitoring the effects of therapeutical measures taken towards arthritic diseases in most mammals utilizes an immunoassay to detect fragments of collagen type II resulting from collagenase activity comprising an antibody directed against an epitope comprised in the amino acid sequence HRGYPGLDG, located in the helical region of collagen type II.

Disclosed are compositions and methods for performing an immuno-assay that includes measuring the amount of an isomerised or optically inverted non-collagen protein derived from cartilage.

0Type II collagen degradation is measurable using a sandwich immunoassay in which a single antibody specific for the amino acid sequence EKGPDP is used to form each side of antibody-collagen fragment-antibody sandwich complexes and the amount of said complexes is measured.

Sandwich assays for collagen fragments

An enzyme preparation comprising (a) first enzyme with xylanase activity and (b) a second enzyme having cellulotytic, xylanolytic or pectinolytic activity and are supported by the specification.

Enzymes with xylanase activity from aspergillus aculeatus

Growing community of inventors

Gentofte, Denmark

Stephan Christgau